Literature DB >> 9740084

Cause of death in men diagnosed with prostate carcinoma.

W A Satariano1, K E Ragland, S K Van Den Eeden.   

Abstract

BACKGROUND: Prostate carcinoma is one of the leading causes of death in men. Although the mortality rate is high, it still may underestimate the number of deaths associated with the disease. This study was conducted to compare causes of death among men previously diagnosed with prostate carcinoma and to examine the extent to which differences in cause of death (death from prostate carcinoma vs. death from other causes) varied by age, race, clinical factors, and comorbid conditions.
METHODS: A review was conducted of the medical records of decedent members of the Kaiser Permanente Medical Care program who previously were diagnosed with prostate carcinoma between January 1980 and December 1984 (n=584). The review focused on demographic factors, symptoms, diagnostic tests, stage of disease, and treatment. Data on comorbidity were obtained from a computerized discharge summary. Logistic regression analysis was used to estimate odds ratios.
RESULTS: Approximately 54% of the decedent prostate carcinoma patients died of their prostate carcinoma. Decedents who were black, age < or = 65 years, diagnosed with more advanced disease stage, recipients of hormonal therapy, and whose death occurred > 6 months after diagnosis were more likely than others to die of prostate carcinoma. In contrast, the likelihood of dying of some other cause was associated with concurrent cardiovascular disease, after adjustment for the effects of race, age, and disease stage. There also were significant two-way age-race and age-time-to-death interactions.
CONCLUSIONS: The prognostic significance of cardiovascular disease in prostate carcinoma patients should be investigated in subsequent survival studies. A number of questions need to be addressed delineating the complex relations between coexisting diseases and their treatment.

Entities:  

Mesh:

Year:  1998        PMID: 9740084     DOI: 10.1002/(sici)1097-0142(19980915)83:6<1180::aid-cncr18>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  30 in total

Review 1.  Androgen deprivation therapy for prostate cancer: implications for cardiometabolic clinical care.

Authors:  L Collins; N Mohammed; T Ahmad; S Basaria
Journal:  J Endocrinol Invest       Date:  2012-02-28       Impact factor: 4.256

Review 2.  Innovations in the systemic therapy of prostate cancer.

Authors:  Dale R Shepard; Derek Raghavan
Journal:  Nat Rev Clin Oncol       Date:  2009-12-08       Impact factor: 66.675

3.  S100A4 accelerates tumorigenesis and invasion of human prostate cancer through the transcriptional regulation of matrix metalloproteinase 9.

Authors:  Mohammad Saleem; Mee-Hyang Kweon; Jeremy James Johnson; Vaqar Mustafa Adhami; Irina Elcheva; Naghma Khan; Bilal Bin Hafeez; Kumar M R Bhat; Sami Sarfaraz; Shannon Reagan-Shaw; Vladimir S Spiegelman; Vijayasaradhi Setaluri; Hasan Mukhtar
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-21       Impact factor: 11.205

Review 4.  Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Dipti Gupta; Chadi Salmane; Susan Slovin; Richard M Steingart
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

5.  What do prostate cancer patients die of?

Authors:  Matias Riihimäki; Hauke Thomsen; Andreas Brandt; Jan Sundquist; Kari Hemminki
Journal:  Oncologist       Date:  2011-01-21

6.  Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols.

Authors:  S Gupta; K Hastak; N Ahmad; J S Lewin; H Mukhtar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

7.  Evaluating long-term patient-centered outcomes following prostate cancer treatment: findings from the Michigan Prostate Cancer Survivor study.

Authors:  May Darwish-Yassine; Manijeh Berenji; Diane Wing; Glenn Copeland; Raymond Y Demers; Carol Garlinghouse; Angela Fagerlin; Gail E Newth; Laurel Northouse; Margaret Holmes-Rovner; David Rovner; Jerry Sims; John T Wei
Journal:  J Cancer Surviv       Date:  2013-11-10       Impact factor: 4.442

8.  Voltage-gated Na+ channels confer invasive properties on human prostate cancer cells.

Authors:  Eric S Bennett; Beth A Smith; Jean M Harper
Journal:  Pflugers Arch       Date:  2003-12-16       Impact factor: 3.657

9.  Green tea catechins suppress the DNA synthesis marker MCM7 in the TRAMP model of prostate cancer.

Authors:  Susan McCarthy; Andrea Caporali; Steve Enkemann; Maurizio Scaltriti; Steve Eschrich; Pierpaola Davalli; Arnaldo Corti; Alice Lee; Jimmy Sung; Timothy J Yeatman; Saverio Bettuzzi
Journal:  Mol Oncol       Date:  2007-09       Impact factor: 6.603

10.  Prostate cancer treatment does not increase the risk of cardiovascular events.

Authors:  Makarand V Khochikar
Journal:  Indian J Urol       Date:  2007-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.